Evidence map›Paper›PMID 39624235›Full record

ArticleJHEP reports : innovation in hepatology2024

Fecal deoxycholic acid associates with diet, intestinal microbes, and total bilirubin in primary sclerosing cholangitis.

Connie Chan, Mateus Lemos, Peter Finnegan, William Gagnon, Richard Dean, Maryam Yazdanafar, Joseph Zepeda, Marie-Claude Vohl, Michael Trauner, Joshua R Korzenik and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Connie ChanDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, CA, USA.
Mateus LemosDepartment of Food Science and Technology, University of California Davis, Davis, CA, USA.
Peter FinneganDepartment of Food Science and Technology, University of California Davis, Davis, CA, USA.
William GagnonFaculty of Pharmacy, Université Laval, Quebec, Canada.
Richard DeanDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, CA, USA.
Maryam YazdanafarDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, CA, USA.
Joseph ZepedaDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, CA, USA.
Marie-Claude VohlSchool of Nutrition and Centre Nutrition, Santé et société, Université Laval, Quebec, Canada.
Michael TraunerDivision of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Joshua R KorzenikDivision of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA.
Olivier BarbierFaculty of Pharmacy, Université Laval, Quebec, Canada.
Maria L MarcoDepartment of Food Science and Technology, University of California Davis, Davis, CA, USA.
Christopher L BowlusDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with a strong association with inflammatory bowel disease and variable disease progression. We aimed to gain insights into the role of fecal bile acids (BA) on disease progression by determining the relationships between fecal BA, diet, and gut microbes, with markers of disease progression, BA synthesis, and farnesoid X receptor (FXR) activity. Methods: BA levels in serum and stool, dietary intake, and markers of BA synthesis, and FXR activity were measured in 26 patients with early stage, large duct PSC. Fecal microbiota were quantified by 16S rRNA gene sequencing. Results: Compared with controls, fecal unconjugated deoxycholic acid (DCA) levels were lower in patients with PSC ( Conclusions: Alcohol intake, Impact and implications: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease with a direct interaction between the gut and the liver. In this study of patients with early-stage PSC, levels of fecal deoxycholic acid correlated with serum total bilirubin, a marker of clinical outcomes. In addition,

Indexed as

Bile acidsCholestatic liver diseaseDietDisease progressionMicrobes

Identifiers

PMID39624235
PMCPMC11609371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.